_1777294007302_731105501.png&w=48&q=75){kind=small}
European Approval for Sight-Restoring Chip
Science Corporation has developed a new device called PRIMA to restore vision in patients with age-related macular degeneration. It has received European regulatory approval and a special classification from the U.S. Food and Drug Administration (FDA). The device relies on a simple surgical procedure in which an electronic chip is implanted behind the eye, and glasses equipped with a camera transfer images to the chip, which stimulates the retina, restoring part of the patients' ability to see. The device has achieved remarkable successes—one patient was able to read a 300-page novel, another solved puzzles, and another painted a picture. Although the cost is expected to reach hundreds of thousands of dollars, the company plans to launch the device commercially in Europe and Germany within the upcoming months. The goal is to improve the quality of life for millions of people worldwide affected by this disease, with future versions and technological enhancements for the eyes and accompanying glasses in development.
Notice: This Is an AI-Generated Summary
Comments (0)